['eosinophilic asthma']
['anb020', 'placebo']

        Inclusion Criteria:

          -  Male and female patients aged ≥18 to ≤65 years and able to give informed consent.

          -  Patients with a confirmed clinical diagnosis of eosinophilic asthma

          -  History of diagnosis of eosinophilic asthma

          -  Severe asthma diagnosed according to the Global Initiative for Asthma (GINA) 2016

          -  Body mass index (BMI) of 18 to 38 kg/m2 (inclusive) and total body weight >50 kg (110
             lb.).

          -  Women of childbearing potential must have a negative serum pregnancy test at screening
             and be willing to use effective methods of contraception throughout the study.

          -  Male patients must be willing to use effective methods of contraception during the
             entire study period.

          -  Patient must be on high dose ICS plus LABA.

          -  Willing and able to comply with the study protocol requirements.

          -  Have the ability to read and understand the study procedures and can communicate
             meaningfully with the Investigator and staff.

        Exclusion Criteria:

          -  Have concomitant medical condition(s) which may interfere with the Investigator's
             ability to evaluate the patient's response to the IP.

          -  Have experienced severe life threatening anaphylactic reactions.

          -  Have received any IP within a period of 3 months or 5 half lives of an IP

          -  Have received high dose systemic corticosteroids

          -  Have received treatment with biologics within 3 months or 5 half lives (whichever is
             longer) before screening.

          -  Abnormal ECG assessment at screening

          -  Uncontrolled hypertension, or acute ischemic cardiovascular diseases.

          -  If female, is pregnant or lactating, or intend to become pregnant during the study
             period.

          -  History (or suspected history) of alcohol or substance abuse within 2 years before
             screening.

          -  Any comorbidity that the Investigator believes is a contraindication to study
             participation.

          -  Have any other physical, mental, or medical conditions which, in the opinion of the
             Investigator, make study participation inadvisable or could confound study
             assessments.

          -  Planned surgery during the study or 30 days before screening.

          -  History of malignancy within 5 years, except non melanoma skin cancer which has been
             fully treated with no current active disease.
      